Luminex has started clinical and analytical studies aimed at evaluating its ARIES Group B Streptococcus (GBS) assay.
Clinical trials are being carried out at several clinical laboratories throughout the US.
Luminex president Homi Shamir said: "We continue to build momentum in our commercial launch schedule for the ARIES platform with the start of clinical trials for GBS, the third assay in the ARIES pipeline.
"The progression of our ARIES menu with assays that are important to patient care continues and the Group B Strep assay is a key contributor due to the high prevalence and potentially serious or life threatening consequences to newborns."
Also known as Streptococcus agalactiae, GBS forms colonies in one in four pregnant women, and if left untreated, can be transmitted to a newborn during labour and delivery, potentially resulting in sepsis, pneumonia or meningitis.
Designed to fit seamlessly into a lean laboratory environment, ARIES enhances laboratory performance and increases efficiency by using internal barcode scanning and other advanced features to minimise operator errors.
The sample to answer system also features two independent magazine modules that support from one to six cassettes each, enabling STAT and batch testing.
Simultaneous in-vitro diagnostic and laboratory developed tests operate through a common universal assay protocol, while an integrated PC eliminates the requirement for a separate computer, stand-alone keyboard and mouse, maximising valuable bench space.
Luminex expects to move forward with its US Food and Drug Administration submission for the ARIES platform and ARIES HSV 1&2 Assay later in 2015.
Image: Clinical trials for the ARIES GBS assay are being conducted at multiple clinical laboratories across the US. Photo: courtesy of 2006-2015 Luminex Corporation.